Florian Wagenlehner
Florian Wagenlehner is an expert in Urology at Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie (Germany). As of October 2026, ScienceLeadR ranks Florian Wagenlehner in the top 1% of experts worldwide for Urinary Tract Infections, Prostatitis and Cystitis. Florian Wagenlehner has authored 747 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 5 of them ongoing. SLR score: 2,421 (community average: 125). How the SLR is computed.
LeadR Profile
Urology
Subspecialties: Infectiology - Surgery - Nephrology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 747
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Total en Bloc Urethra Preservation at Robot-Assisted Prostatectomy (ToP-RAP): A Prospective IDEAL Stage 1-2a Study. PMID 42882829 — feasibility studies, minimally invasive surgical procedures, safety, prostate, recycling, robotic surgical procedures, urethra, prostatic neoplasms, therapeutics, prostatectomy, urinary incontinence | Cancers (Basel) | 2026 | 0 |
| [Administration of antibiotics in patients with polytrauma-based urogenital injuries-a narrative review]. PMID 42862284 — urology, antibiotic prophylaxis, antimicrobial stewardship, multiple trauma, wounds and injuries | Urologie | 2026 | 0 |
| The Surgical Management of Prostate Cancer in Renal Transplant Recipients: The Minimally Invasive Approach. PMID 42858064 — lymph nodes, neoplasms, prostate, lymph, prostatic neoplasms, transplants, prostatectomy, catheters | J Vis Exp | 2026 | 0 |
| Rhabdomyolysis Following Robot-Assisted Radical Prostatectomy. PMID 42858063 — diabetes mellitus, neoplasms, prostate, prostatic neoplasms, obesity, rhabdomyolysis, prostatectomy | J Vis Exp | 2026 | 0 |
| Storage-dependent changes in the soluble urinary proteome: a pre-analytical stability study in inflammatory clinical urine samples. PMID 42835602 — pyelonephritis, proteomics, proteome, temperature | J Liq Biopsy | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Total en Bloc Urethra Preservation at Robot assisted Prostatectomy IDEAL Stage 2a NCT07678489 — urinary bladder, feasibility studies, genes, ras, neoplasms, prostate, urethra, prostatic neoplasms, therapeutics, prostatectomy, urinary incontinence, neck | N/A | Recruiting | 2024 |
| Treatment combination of Durvalumab Tremelimumab Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin 2023-507342-84-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, cystectomy, therapeutics | Phase 3 | Active not recruiting | 2021 |
| A clinical study to investigate the antibacterial efficacy of arbutin metabolites in urine 2024-519011-34-00 — arbutin | Phase 1 | Active not recruiting | 2025 |
| PROCARE PROstate Cancer Real World Evidence Registry NCT06835218 — registries, neoplasms, prostate, hormones, neoplasm metastasis, prostatic neoplasms, castration, therapeutics | N/A | Recruiting | 2024 |
| A Trial Comparing Docetaxel 75 mg m2 (3w) Versus Docetaxel 50 mg m2 (2w) in Combination With Darolutamide ADT in mHSPC Patients NCT05676203 — androgen antagonists, safety, docetaxel, androgens, neoplasms, prostate, hormones, physicians, prostatic neoplasms, therapeutics | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map